ReviewImaginem oblivionis: the prospects of neuroimaging for early detection of Alzheimer's disease☆,☆☆
Introduction
Alzheimer's disease (AD) is a progressive neurodegenerative disorder characterised by the gradual onset of dementia,1 leading invariably to death, usually between 7 and 10 years after diagnosis. Age is the major risk factor. AD is the leading cause of dementia in the elderly and affects about 5% of individuals at age 65, with its prevalence increasing exponentially with each successive decade, with 10–15% and 20–30% of 75- and 85-year olds affected, respectively.
Section snippets
Clinical features and diagnostic criteria
The clinical diagnosis of AD is currently based on progressive memory impairment and decline in at least one other cognitive domain, and by excluding other diseases such as frontotemporal dementia, dementia with Lewy-bodies (DLB), stroke, brain tumour, normal pressure hydrocephalus or depression, that might also present with dementia.[2], [3]
The clinical diagnostic accuracy for AD depends on the stage of disease and can exceed 90% in academic settings in mid or late stages.4 Diagnostic criteria
Genetic predisposing factors
While mutations of the PS-1, PS-2,11 and amyloid precursor protein (APP) genes – resulting in increased production and elevated plasma levels of amyloid-β protein – on chromosomes 1, 14, and 21, respectively, have been associated with the rare form of familial AD, the only consistent marker for the late-onset non-familial form of dementia is the apolipoprotein ε allele on chromosome 19.12 This refers specifically to the ε4 allele, though it is absent in approximately 30–40% of patients with AD
Neuropathologic features
By means of clinical, laboratory, and imaging evidence only a provisional diagnosis of either possible or probable AD can be made in living subjects. In the absence of biologic markers, direct pathologic examination of brain tissue derived from either biopsy or autopsy remains the only definitive method for establishing a diagnosis of AD.15
The typical macroscopic picture is gross cortical atrophy. Microscopically, there is widespread cellular degeneration and neuronal loss that affects
Structural neuroimaging
Structural neuroimaging techniques, such as computed tomography (CT) and magnetic resonance imaging (MRI), are routinely used in the clinical evaluation of AD patients.
Widespread cortical atrophy with a thinning of medial temporal lobe structures are the most consistent structural neuroimaging findings associated with AD,26 though not pathognomonic of the disease because there is overlap with “normal” aging.
CT is mainly used to exclude other treatable causes of dementia.27 Studies reporting
Amyloid imaging
Extracellular amyloid plaques are the hallmark brain lesions of sporadic Alzheimer's disease. These microscopic Aβ aggregates91 are well beyond the resolution of the usual neuroimaging techniques used for the evaluation of patients with AD. Furthermore, current techniques focus on non-specific features derived mainly from neuronal loss and atrophy, which are late features in the progression of the disease, and are secondary to the basic functional alteration. However, the distribution and
Novel therapeutic approaches
Neuronal degeneration with impairment in cholinergic transmission in hippocampal and cortical areas associated with memory and cognition are characteristic of AD. No current therapy has been shown to halt or reverse the underlying disease process. Though now approved for AD, the cholinesterase inhibitors tacrine, donepezil, rivastigmine, and galantamine only provide patients with modest relief to their symptoms.142 Recently, the non-competitive NMDA antagonist memantine has been proposed as a
Conclusions
While clinical criteria together with current structural neuroimaging techniques (CT or MRI) are sensitive and specific enough for the diagnosis of AD at the mid or late stages of the disease, the development of a reliable method of assessing Aβ amyloid burden in vivo may permit early diagnosis at presymptomatic stages, more accurate differential diagnosis, while also allowing treatment follow up.
The criteria for the diagnosis, management, and early detection of dementia[62], [167], [168]
Acknowledgements
This work is supported in part by grants from the National Health and Medical Research Council of Australia, Prana Biotechnology, and Schering AG.
References (171)
- et al.
Two novel presenilin-1 mutations (Y256S and Q222H) are associated with early-onset Alzheimer's disease
Neurobiol. Aging
(2003) - et al.
Causative and susceptibility genes for Alzheimer's disease: a review
Brain Res. Bull.
(2003) Neuropathology of Alzheimer's disease and related disorders
Neurol. Clin.
(2000)- et al.
Volumes of the entorhinal and perirhinal cortices in Alzheimer's disease
Neurobiol. Aging
(1998) - et al.
Early diagnosis of Alzheimer's disease; contribution of structural neuroimaging
Neuroimage
(2003) - et al.
Structural magnetic resonance imaging in the practical assessment of dementia: beyond exclusion
Lancet Neurol.
(2002) - et al.
MRI of entorhinal cortex in mild Alzheimer's disease
Lancet
(1999) - et al.
MRI-derived entorhinal and hippocampal atrophy in incipient and very mild Alzheimer's disease
Neurobiol. Aging
(2001) - et al.
Application of positron emission tomography for evaluation of metabolism and blood flow in human brain: normal development, aging, dementia, and stroke
Mol. Genet. Metab.
(2001) - et al.
Alzheimer's disease histologically proven studied by MRI and MRS: two cases
Magn. Reson. Imaging
(1993)
Deficits in cerebral glucose metabolism demonstrated by positron emission tomography in individuals at risk of familial Alzheimer's disease
Neurosci. Lett.
Imaging brain cholinergic activity with positron emission tomography: its role in the evaluation of cholinergic treatments in Alzheimer's dementia
Biol. Psychiatry
Synthesis of an I-123 analog of A-85380 and preliminary SPECT imaging of nicotinic receptors in baboon
Nucl. Med. Biol.
Clinical studies in Alzheimer patients with positron emission tomography
Behav. Brain Res.
Tacrine restores cholinergic nicotinic receptors and glucose metabolism in Alzheimer patients as visualized by positron emission tomography
Neurobiol. Aging
Visualization of fibrillar amyloid deposits in living, transgenic Caenorhabditis elegans animals using the sensitive amyloid dye, X-34
Neurobiol. Aging
Development of small molecule probes for the beta-amyloid protein of Alzheimer's disease
Neurobiol. Aging
Uncharged thioflavin-T derivatives bind to amyloid-beta protein with high affinity and readily enter the brain
Life Sci.
Diagnosis of Alzheimer's disease
Arch. Neurol.
Alzheimer's disease: etiologies, pathophysiology, cognitive reserve, and treatment opportunities
Neurology
Neuropathologic diagnostic outcomes from a cohort of outpatients with suspected dementia
J. Gerontol. A Biol. Sci. Med. Sci.
Accuracy of clinical diagnosis of Alzheimer disease and clinical features of patients with non-Alzheimer disease neuropathology
Alzheimer Dis. Assoc. Disord.
Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease
Neurology
Mild cognitive impairment: transition between aging and Alzheimer's disease
Neurologia
Apolipoprotein E status as a predictor of the development of Alzheimer's disease in memory-impaired individuals
JAMA
Mild cognitive impairment: clinical characterization and outcome
Arch. Neurol.
Utility of the apolipoprotein E genotype in the diagnosis of Alzheimer's disease: Alzheimer's Disease Centers Consortium on apolipoprotein E and Alzheimer's disease
N. Engl. J. Med.
Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families
Science
Alzheimer's disease: genotypes, phenotypes, and treatments
Science
Tau neurofibrillary pathology and microtubule stability
J. Mol. Neurosci.
Neuropathology of Alzheimer's disease: a critical update
J. Neural. Transm. Suppl.
The molecular pathology of amyloid deposition in Alzheimer's disease
Mol. Neurobiol.
Amyloid precursor protein (APP) and beta A4 amyloid in the etiology of Alzheimer's disease: precursor–product relationships in the derangement of neuronal function
Brain Pathol.
Wisniewski and the amyloid theory of Alzheimer's disease
J. Alzheimers Dis.
Detection in life of confirmed Alzheimer's idsease using a simple measurement of medial temporal lobe atrophy by computed tomography
Lancet
Structural neuroimaging of Alzheimer's disease and other dementias
Aging
Medial temporal lobe width on CT scanning in Alzheimer's disease; comparison with vascular dementia, depression and dementia with Lewy bodies
Dement. Geriatr. Cogn. Disord.
Magnetic resonance imaging of the entorhinal cortex and hippocampus in mild cognitive impairment and Alzheimer's disease
J. Neurol. Neurosurg. Psychiatry
A critical discussion of the role of neuroimaging in mild cognitive impairment
Acta Neurol. Scand. Suppl.
Usefulness of MRI measures of entorhinal cortex versus hippocampus in AD
Neurology
A comparison of medial and lateral temporal lobe atrophy in dementia with Lewy bodies and Alzheimer's disease: magnetic resonance imaging volumetric study
Dement. Geriatr. Cogn. Disord.
Use of structural magnetic resonance imaging to predict who will get Alzheimer's disease
Ann. Neurol.
MRI measures of entorhinal cortex vs hippocampus in preclinical AD
Neurology
Neuroimaging and early diagnosis of Alzheimer disease: a look to the future
Radiology
Cited by (50)
Aβ-amyloid and Tau Imaging in Dementia
2017, Seminars in Nuclear MedicineAmyloid imaging: Past, present and future perspectives
2016, Ageing Research ReviewsCitation Excerpt :While clinical criteria together with current structural neuroimaging techniques are sensitive and specific enough for the diagnosis of AD at the mid or late stages of the disease, the development of a reliable method of assessing Aβ burden in vivo has allowed early diagnosis at presymptomatic stages, more accurate differential diagnosis, as well as treatment follow up. ( Villemagne et al., 2005). Moreover, Quantitative imaging of Aβ burden in vivo has provided insights into the relationship between Aβ burden and clinical and neuropsychological characteristics in the AD spectrum as well in other neurodegenerative conditions where Aβ plays a role.
Amyloid Imaging with PET in Early Alzheimer Disease Diagnosis
2013, Medical Clinics of North AmericaCitation Excerpt :PET is a sensitive molecular imaging technique that allows in vivo quantification of radiotracer concentrations in the picomolar range, allowing the noninvasive assessment of molecular processes at their sites of action, and is capable of detecting disease processes at asymptomatic stages when there is no evidence of anatomic change on MRI.25 Because Aβ is at the center of AD pathogenesis, and given that several pharmacologic agents aimed at reducing Aβ levels in the brain are being developed and tested, many efforts have been focused on generating radiotracers for imaging Aβ in vivo.26,27 As a quantitative neuroimaging probe, the Aβ radiotracer must possess several key general properties: it should be a lipophilic, nontoxic small molecule with a high specificity and selectivity for Aβ and amenable for high specific activity labeling with fluorine-18 (18F) or other long-lived radioisotopes, with no radiolabeled metabolites that enter the brain, while reversibly binding to Aβ in a specific and selective fashion.28–30
<sup>99m</sup>Tc-labeled dibenzylideneacetone derivatives as potential SPECT probes for in vivo imaging of β-amyloid plaque
2013, European Journal of Medicinal ChemistryDiagnostic imaging of Alzheimer's disease with copper and technetium complexes
2012, Coordination Chemistry ReviewsCitation Excerpt :This approach can be extended to correlations between the patterns of change of regional cerebral blood flow as measured by SPECT imaging using [TcVO(HMPAO)] and the level of episodic memory performance in subjects with AD [89]. Reviews, with a more clinical perspective than what is provided here, and that cover the application of measurements of cerebral blood flow using SPECT to differentially diagnose AD from other dementias are available [90–94]. Ligands containing a mixture of amide, amine and mecapto donor atoms are commonly used as a quadridentate ligand platform to form stable complexes with [TcVO]3+ cores.
Intraindividual cognitive decline using a brief computerized cognitive screening test
2012, Alzheimer's and DementiaCitation Excerpt :In addition, we also plan to evaluate brain amyloid accumulation (as well as PET, MRI, neuropsychological and subjective report findings) in matched nondeclining participants to ensure that memory decline correlates with enrichment for amyloid pathology rather than nonspecific study participation factors, and to replicate previous findings in nondeclining participants [40]. Several other techniques using neuroimaging, CSF, or blood samples have shown promise as biomarkers for early AD pathology [43–49]. The findings of the current study suggest that serial computerized cognitive evaluation of memory may also be considered as a potential early marker of AD pathology, perhaps as a noninvasive, low cost, brief, and widely accessible screening test for persons considered at risk of cognitive decline but who are otherwise healthy and for whom further consideration of more specific evaluations may then be appropriate.
- ☆
Supported in part by grants from the National Health and Medical Research Council of Australia, Prana Biotechnology and Schering AG.
- ☆☆
Quo pacto dicam imaginem oblivionis teneri memoria mea, non ipsam oblivionem, cum eam memini? (How can I assert that the image of oblivion is retained by my memory, and not oblivion itself, when I remember it?) St Augustine. . Liber X, Caput 16.